2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2005121375v1 17/8/2193    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sun, G.-P. Articles by Nishiyama, A. Search for Related Content PubMed PubMed Citation Articles by Sun, G.-P. Articles by Nishiyama, A.

Involvements of Rho-Kinase and TGF- Pathways in Aldosterone-Induced Renal Injury

Guang-Ping Sun^*,, Masakazu Kohno^*, Peng Guo^*, Yukiko Nagai, Kayoko Miyata, Yu-Yan Fan, Shoji Kimura, Hideyasu Kiyomoto^*, Koji Ohmori^*, De-Tian Li, Youichi Abe and Akira Nishiyama

^* Department of CardioRenal and Cerebrovascular Medicine, Life Science Research Center Department of Pharmacology, Kagawa University Medical School, Kagawa, Japan; and Department of Nephrology, the Second Affiliated Hospital of China Medical University, Shenyang, China

Address correspondence to: Dr. Akira Nishiyama, Department of Pharmacology, Kagawa University Medical School, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan. Phone: +81-87-898-5111, ext. 2502; Fax: +81-87-891-2126; E-mail: akira{at}kms.ac.jp

Received for publication December 28, 2005. Accepted for publication May 7, 2006.

Recent studies have suggested a role for aldosterone in the pathogenesis of renal injury. This study investigated the potential contributions of Rho-kinase and TGF- pathways to aldosterone-induced renal injury. Rats were uninephrectomized and then treated for 5 wk with 1% NaCl in a drinking solution and one of the following: Vehicle (2% ethanol, subcutaneously; n = 9); aldosterone (0.75 µg/h, subcutaneously; n = 9); or aldosterone + fasudil, a specific Rho-kinase inhibitor (10 mg/kg per d, subcutaneously; n = 8). Phosphorylation of myosin phosphate target subunit-1 (MYPT1) and Smad2/3 in renal cortical tissue was measured by Western blotting with anti-phospho MYPT1 and Smad2/3 antibodies, respectively. Rats that received aldosterone infusion exhibited hypertension and severe renal injury characterized by proteinuria, glomerular sclerosis, and tubulointerstitial fibrosis with increases in -smooth muscle actin staining and numbers of monocytes/macrophages in the interstitium. Renal cortical mRNA levels of types I and III collagen, TGF-, connective tissue growth factor, and monocyte chemoattractant protein-1 as well as Smad2/3 phosphorylation were significantly increased in rats that received aldosterone infusion. All of these changes were associated with an increase in renal tissue MYPT1 phosphorylation. Treatment with fasudil did not alter BP but significantly ameliorated proteinuria and renal injury in rats that received aldosterone infusion. Furthermore, fasudil prevented MYPT1 phosphorylation and markedly decreased -smooth muscle actin staining, numbers of monocytes/macrophages, mRNA levels of types I and III collagen, TGF-, connective tissue growth factor and monocyte chemoattractant protein-1, and Smad2/3 activity in renal cortical tissues. These results provide evidence, for the first time, that Rho-kinase is substantially involved in aldosterone-induced renal injury through activation of a TGF-–dependent pathway.

This article has been cited by other articles:

				J. Prakash, M. H. de Borst, M. Lacombe, F. Opdam, P. A. Klok, H. van Goor, D. K.F. Meijer, F. Moolenaar, K. Poelstra, and R. J. Kok Inhibition of Renal Rho Kinase Attenuates Ischemia/Reperfusion-Induced Injury J. Am. Soc. Nephrol., November 1, 2008; 19(11): 2086 - 2097. [Abstract] [Full Text] [PDF]

				V. Kolavennu, L. Zeng, H. Peng, Y. Wang, and F. R. Danesh Targeting of RhoA/ROCK Signaling Ameliorates Progression of Diabetic Nephropathy Independent of Glucose Control Diabetes, March 1, 2008; 57(3): 714 - 723. [Abstract] [Full Text] [PDF]

				H. Ikeda, Y. Kume, K. Tejima, T. Tomiya, T. Nishikawa, N. Watanabe, N. Ohtomo, M. Arai, C. Arai, M. Omata, et al. Rho-kinase inhibitor prevents hepatocyte damage in acute liver injury induced by carbon tetrachloride in rats Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G911 - G917. [Abstract] [Full Text] [PDF]

				P. Rivera, M. P. Ocaranza, S. Lavandero, and J. E. Jalil Rho Kinase Activation and Gene Expression Related to Vascular Remodeling in Normotensive Rats With High Angiotensin I Converting Enzyme Levels Hypertension, October 1, 2007; 50(4): 792 - 798. [Abstract] [Full Text] [PDF]

				Y. Ozawa and H. Kobori Crucial role of Rho-nuclear factor-{kappa}B axis in angiotensin II-induced renal injury Am J Physiol Renal Physiol, July 1, 2007; 293(1): F100 - F109. [Abstract] [Full Text] [PDF]

				K. Hayashi, S. Wakino, N. Sugano, Y. Ozawa, K. Homma, and T. Saruta Ca2+ Channel Subtypes and Pharmacology in the Kidney Circ. Res., February 16, 2007; 100(3): 342 - 353. [Abstract] [Full Text] [PDF]

				J. Song, C. K. Kost Jr., and D. S. Martin Androgens potentiate renal vascular responses to angiotensin II via amplification of the Rho kinase signaling pathway Cardiovasc Res, December 1, 2006; 72(3): 456 - 463. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673